Moderna, Inc. (NASDAQ:MRNA) | WebDisclosure

Switch to English

11309	Sociétés
251324	Mots-clés
180388	Articles
137138	Communiqués

Accueil
Sociétés
Moderna, Inc.

COMMUNIQUÉ DE PRESSE

publié le 31/01/2024 à 23:45, il y a 2 années 9 mois

Moderna Named to Fortune's List of World's Most Admired Companies
Moderna, Inc. has been recognized on Fortune's World's Most Admired Companies list, positioning among the top-50 companies. The company focuses on mRNA medicine for disease prevention and treatment, recognized for innovation and public health impact

Moderna Inc. Fortune Most Admired Companies MRNA Medicine Corporate Reputation
COMMUNIQUÉ DE PRESSE

publié le 08/01/2024 à 13:00, il y a 2 années 10 mois

Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Moderna, Inc. (NASDAQ: MRNA) announces impressive financial updates for 2023, with approximately $6.7 billion in product sales and an increased COVID-19 market share in the U.S. The company reiterates the expectation of approximately $4 billion in product sales for 2024, highlighting upcoming late-stage programs with anticipated milestones in 2024 and 2025. The nine late-stage programs include respiratory vaccines, next-generation COVID-19 vaccine, seasonal flu vaccine, combination vaccine against seasonal flu and COVID-19, cytomegalovirus (CMV) vaccine, individualized neoantigen therapy (INT), and rare disease therapeutics. Moderna focuses on returning to sales growth in 2025 and expects to break even in 2026 through product launches and disciplined investment. For further details, Jamey Mock will present an update on the Company and its pipeline of mRNA development programs at the 42nd Annual J.P. Morgan Healthcare Conference on January 8th, 2024, at 3:45 p.m. PT/6:45 p.m. ET.

Moderna Inc Financial Updates COVID-19 Market Share Late-stage Programs MRNA Development Programs
COMMUNIQUÉ DE PRESSE

publié le 20/12/2023 à 22:05, il y a 2 années 10 mois

Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
COMMUNIQUÉ DE PRESSE

publié le 15/12/2023 à 00:00, il y a 2 années 10 mois

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
COMMUNIQUÉ DE PRESSE

publié le 14/12/2023 à 12:30, il y a 2 années 10 mois

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comp
COMMUNIQUÉ DE PRESSE

publié le 12/12/2023 à 14:00, il y a 2 années 10 mois

Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
COMMUNIQUÉ DE PRESSE

publié le 07/12/2023 à 13:00, il y a 2 années 11 mois

Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
COMMUNIQUÉ DE PRESSE

publié le 14/11/2023 à 13:00, il y a 2 années 11 mois

Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
COMMUNIQUÉ DE PRESSE

publié le 08/11/2023 à 22:15, il y a 3 années

Moderna to Present at Upcoming Conferences in November 2023
COMMUNIQUÉ DE PRESSE

publié le 08/11/2023 à 13:00, il y a 3 années

Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event

Les Echos

Publié le 10/11/2026 à 14:00, il y a 16 minutes

Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 2 au 6 novembre 2026
Publié le 10/11/2026 à 14:00, il y a 16 minutes

Guillemot Corporation S.A. | Weekly report share buyback from November 2 to November 6, 2026
Publié le 10/11/2026 à 11:02, il y a 3 heures 13 minutes

Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 31 octobre 2026
Publié le 10/11/2026 à 11:02, il y a 3 heures 13 minutes

Statement about the number of shares composing the share capital and the number of voting rights as of October 31, 2026
Publié le 10/11/2026 à 07:00, il y a 7 heures 16 minutes

bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 10/11/2026 à 14:00, il y a 16 minutes

Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
Publié le 10/11/2026 à 14:00, il y a 16 minutes

Four Nines Gold Intersects 67 Metres at 1.78 g/t Gold, Reinforing Emerging Gold Corridor at Hayden Hill
Publié le 10/11/2026 à 13:30, il y a 46 minutes

Adcore Reports Third Quarter 2026 Results: Gross Margin Rises to 64%, Operating Loss Halved, Cash Up to $4.3 Million as Restructuring Takes Hold
Publié le 10/11/2026 à 13:30, il y a 46 minutes

Nextech3D.ai to Report Fiscal Second Quarter 2027 Financial Results and Host Investor Webinar on November 19, 2026 at 4:30 PM ET
Publié le 10/11/2026 à 13:30, il y a 46 minutes

Sterling Metals Announces Fully Allocated Private Placement of Units, Flow-Through Shares and Charity Flow-Through Units

Voir tout ACCESSWIRE

EQS Group

Publié le 10/11/2026 à 14:05, il y a 11 minutes

Three Researchers Granted Over $1 Million to De-Risk and Progress Preclinical Drug Candidates for Neurodegenerative Diseases
Publié le 10/11/2026 à 14:05, il y a 11 minutes

Rockwell Automation Introduces PanelView Pro to Deliver High-Performance Visualization for Modern Manufacturing
Publié le 10/11/2026 à 13:05, il y a 1 heure 11 minutes

NORTON MOTORCYCLES ENTERS NEW CATEGORY WITH NEW NORTON 450 CC URBAN DEBUT AT EICMA - FULL MATERIALS NOW AVAILABLE
Publié le 10/11/2026 à 13:00, il y a 1 heure 16 minutes

Oakstone Holidays Champions Off-Season Coastal Escapes as UK Holidaymakers Rethink Seaside Breaks
Publié le 10/11/2026 à 12:50, il y a 1 heure 26 minutes

Form 8.3 - Zürcher Kantonalbank: Irish Residential Properties REIT plc